Press Release

<< Back
Printer Friendly Version View printer-friendly version
Editas Medicine to Participate in Investor Conferences in June

CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in June.  Details are as follows:

JMP Securities Life Sciences Conference

Date: Tuesday, June 20, 2017
Panel: Gene Editing - Pushing the Frontier for Curing Disease
Time: 9:00 a.m. ET
Location: New York

Goldman Sachs Third Annual Innovation Symposium

Date: Tuesday, June 27, 2017
Panel: CRISPR - The Era of Gene Editing
Time: 10:15 a.m. ET
Location: New York

About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.  The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Media Contact
Cristi Barnett
Editas Medicine, Inc.
(617) 401-0113
cristi.barnett@editasmed.com

Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com

Primary Logo

Editas Medicine

Print Page    E-mail Page    RSS    E-mail Alerts